Report Highlights

RAS-acting agents at a Turning Point: Market Overview

The global RAS-acting agents market reached USD 3.2 billion in 2024, driven primarily by the commercial launches of sotorasib (Lumakras) and adagrasib (Krazati) for KRAS G12C-mutant non-small cell lung cancer and colorectal cancer. These two products together defined the first viable direct-RAS inhibitor class after decades of scientific failure in targeting what was labeled an "undruggable" oncoprotein. The market trajectory is firmly upward, supported by expanding label indications, combination regimen adoption, and a rich pipeline of next-generation agents addressing broader RAS mutation profiles including G12D, G12V, and pan-RAS inhibition.

The current moment is a structural turning point because the field is transitioning from single-allele covalent inhibition toward broader, non-covalent, and multi-mutation targeting strategies. Revolution Medicines' RMC-6236, a tri-complex pan-RAS inhibitor, entered pivotal trials in 2024 and represents a mechanistic leap beyond existing approved agents. Simultaneously, regulatory agencies in the US and EU are accelerating breakthrough therapy designations for RAS-targeted agents, compressing development timelines. This convergence of mechanistic innovation and regulatory tailwinds is reshaping competitive positioning across the entire oncology pipeline landscape.

Key Forces Shaping RAS-Acting Agent Growth

Three forces are driving revenue growth in this market with specific and measurable mechanisms. First, the expansion of companion diagnostic infrastructure — particularly Guardant Health's liquid biopsy panels and Foundation Medicine's tissue-based CDx platforms — is directly increasing the population of diagnosed, biomarker-selected patients who qualify for RAS-targeted therapy. This alone is projected to expand the addressable treatment pool in the US by 25% by 2027, translating directly into incremental prescription volume for approved agents. NSCLC and colorectal cancer segments in North America benefit most immediately from this diagnostic pull-through.

Second, combination regimen development with MEK inhibitors, SHP2 inhibitors, and anti-EGFR antibodies is converting single-agent therapies into multi-drug regimens, multiplying per-patient revenue per treatment episode. Amgen's Phase III combination study pairing sotorasib with panitumumab in colorectal cancer demonstrated a near doubling of progression-free survival, providing commercial justification for combination labeling that will structurally increase average selling prices. Third, pipeline progression into KRAS G12D and KRAS G12V mutations — which are prevalent in pancreatic ductal adenocarcinoma and carry far higher unmet need — opens an entirely new addressable patient population estimated at 120,000 new US diagnoses annually.

Barriers and Risks in the RAS-acting agents market

The most significant structural risk to this market's growth thesis is the durability of clinical response. Adaptive resistance to KRAS G12C inhibitors develops through multiple mechanisms — KRAS amplification, secondary mutations at Y96 and G13, and bypass signaling through RTK upregulation — and occurs in the majority of patients within six months of monotherapy initiation. This is not a cyclical problem that better trial design solves; it is an intrinsic biological feature of RAS-mutant tumor evolution. Without compelling combination data demonstrating durable response, the premium pricing justification for these agents weakens substantially, particularly under payer pressure from Medicare Drug Price Negotiation under the Inflation Reduction Act.

A secondary but material cyclical risk is clinical trial execution bottlenecks. The RAS-acting agents pipeline comprises over 40 active clinical programs globally as of 2024, creating fierce competition for biomarker-selected patient enrollment — particularly in KRAS G12C NSCLC, where the patient pool is simultaneously being split across first-line, second-line, and combination cohorts. This enrollment competition delays readout timelines, compresses differentiation windows between competing agents, and increases development costs for smaller pipeline companies. Of the two risk categories, the structural resistance biology risk is more dangerous to the long-term growth thesis, as it directly challenges monotherapy commercial longevity.

Emerging Opportunities in RAS-acting agents

The most compelling near-term opportunity is KRAS G12D inhibition in pancreatic ductal adenocarcinoma, a tumor type with a five-year survival rate below 12% and no approved targeted therapy. Mirati's MRTX1133 and Revolution Medicines' RMC-9805 are the most advanced G12D-selective agents, with Phase I/II data expected in 2025 confirming target engagement and early efficacy signals. This opportunity materialises if either compound demonstrates tumor regression in pancreatic cancer patients with confirmed KRAS G12D mutations — an event that would trigger accelerated approval pathways and immediate peak sales projections exceeding USD 2 billion annually given the severity of unmet need.

A second emerging opportunity is the application of RAS-acting agents in hematologic malignancies, specifically NRAS-mutant acute myeloid leukemia and multiple myeloma. NRAS mutations occur in 10–20% of AML cases, and no approved RAS-directed therapy currently addresses this population. Boehringer Ingelheim's BI-2865, a pan-KRAS and NRAS inhibitor, is advancing through Phase I trials in liquid tumor indications. This opportunity requires Phase II proof-of-concept data demonstrating complete remission rates competitive with existing AML standards of care — a condition that, if met, would open a high-value hematology market segment currently untouched by the existing approved RAS inhibitor portfolio.

Investment Case: Bull, Bear, and What Decides It

The bull case for RAS-acting agents rests on three simultaneous catalysts: pivotal trial success for pan-RAS inhibitors in 2025–2026 driven by Revolution Medicines' RMC-6236, approval of the first KRAS G12D-selective agent in pancreatic cancer, and label expansion of existing G12C inhibitors into first-line NSCLC combination regimens. Under this scenario, the total addressable market expands from its current G12C-dominant profile into a pan-RAS, multi-tumor-type market covering lung, colorectal, pancreatic, and hematologic cancers. Market revenues reach USD 7.9 billion by 2034 with sustained above-consensus growth, and the competitive landscape consolidates around three to four dominant platforms with defensible intellectual property in distinct mutation classes.

The bear case materialises if resistance biology proves insurmountable at the combination level, not merely at monotherapy. Specifically, if SHP2 inhibitor combinations fail to extend progression-free survival beyond eight months in KRAS G12C NSCLC — a threshold required to justify combination premium pricing — payers will restrict reimbursement to narrow second-line indications and demand outcomes-based contracting. Simultaneously, if KRAS G12D inhibitors show insufficient single-agent activity in pancreatic cancer, the market's expansion narrative collapses back to a G12C-only niche with a capped patient population. In this scenario, revenue plateaus below USD 5 billion by 2034, and smaller pipeline companies face capital access constraints as investor enthusiasm resets.

The single swing variable is the Phase III readout from Amgen's CodeBreaK 301 combination study and Revolution Medicines' RMC-6236 pivotal data, both anticipated in 2026. If these two datasets collectively demonstrate durable response rates above 50% and progression-free survival exceeding 10 months, the bull case is locked. No other factor — pricing policy, competitive entry, or diagnostic penetration — carries equivalent market-defining weight. The bull case is stronger, and here is the specific reason: the mechanistic shift from covalent G12C-only to non-covalent pan-RAS inhibition solves the resistance problem at its source, and the clinical data trajectory from Phase I/II readouts already supports this conclusion.

Market at a Glance

Regional Performance: Where RAS-acting agents are growing fastest

North America is the largest revenue contributor to the RAS-acting agents market, accounting for an estimated 61% of 2024 global revenues. The US market benefits from the earliest commercial launches of sotorasib and adagrasib, the highest companion diagnostic penetration rates, and the most active clinical trial ecosystem for next-generation agents. Europe is the second largest region, with the EMA granting conditional approval to adagrasib in 2023 and sotorasib earlier, though reimbursement delays in Germany, Italy, and France constrain uptake relative to US commercial performance. Japan is advancing steadily through PMDA review processes for KRAS inhibitors approved in the US, with launches anticipated in 2025 creating incremental regional revenue.

Asia Pacific — led by China — carries the highest growth rate in this market, with a projected regional CAGR of 14.2% through 2034. The specific driver is the disproportionately high prevalence of KRAS-mutant NSCLC among East Asian never-smokers, a population with limited therapeutic alternatives until RAS-directed agents arrived. Chinese domestic biotech firms including BeiGene and Zymeworks China are advancing their own KRAS inhibitor candidates through NMPA pathways, which will accelerate access while creating local competition. Latin America and the Middle East and Africa regions remain commercially nascent for RAS-targeted therapies due to limited biomarker testing infrastructure and high drug costs relative to healthcare budgets, but both markets show structured market development potential over the forecast period.

Leading Market Participants

• Amgen
• Mirati Therapeutics (Bristol-Myers Squibb)
• Revolution Medicines
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Relay Therapeutics
• Eli Lilly
• Roche
• Pfizer
• Turning Point Therapeutics (Bristol-Myers Squibb)

Where RAS-acting agents are headed by 2034

By 2034, the RAS-acting agents market reaches USD 7.9 billion and is structurally unrecognisable from its 2024 form. The market shifts from a two-product, single-mutation, single-tumor-type commercial base to a multi-platform ecosystem spanning at least four distinct mutation classes (G12C, G12D, G12V, pan-RAS), three major tumor types (NSCLC, CRC, PDAC), and a growing hematology segment. Combination regimens become the commercial standard, not the exception, with two-drug and three-drug KRAS-directed combinations carrying average selling prices 2.5 to 3 times higher than current monotherapy list prices. The competitive structure consolidates around three dominant platform companies with deep IP moats in distinct mechanistic classes.

Revolution Medicines and Amgen are best positioned for 2034 leadership for distinct reasons. Revolution Medicines' tri-complex inhibitor platform is mechanistically differentiated and covers pan-RAS rather than allele-specific inhibition, giving it the broadest addressable mutation coverage in the pipeline. Amgen benefits from established oncology commercial infrastructure, a proven reimbursement track record with Lumakras, and the capital to execute combination development programs across multiple tumor types simultaneously. Mirati's portfolio, now integrated within Bristol-Myers Squibb following the 2024 acquisition, adds a second commercially validated KRAS inhibitor and a broad pipeline of next-generation assets with global commercial reach, making BMS the third major force shaping the market's 2034 landscape.

Market Segmentation

By Drug Type

• KRAS G12C Inhibitors
• KRAS G12D Inhibitors
• Pan-RAS Inhibitors
• SHP2 Inhibitors
• MEK Inhibitors
• Combination Regimens

By Indication

• Non-Small Cell Lung Cancer
• Colorectal Cancer
• Pancreatic Ductal Adenocarcinoma
• Acute Myeloid Leukemia
• Multiple Myeloma
• Other Solid Tumors

By Line of Therapy

• First-Line Therapy
• Second-Line Therapy
• Third-Line and Beyond
• Adjuvant Setting

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Frequently Asked Questions

Q1. What is the primary commercial driver of the RAS-acting agents market through 2027? ▼

Label expansion of approved KRAS G12C inhibitors into first-line combination regimens is the primary commercial driver, as it multiplies per-patient revenue per treatment episode. Companion diagnostic penetration enabling broader biomarker screening is the enabling infrastructure condition that makes this expansion commercially executable.

Q2. Why has the RAS oncoprotein historically been considered undruggable, and how has this changed? ▼

RAS lacks a classic deep binding pocket accessible to small molecules in its active GTP-bound state, which stymied drug discovery efforts for over three decades. The identification of a cryptic allosteric pocket specific to the KRAS G12C mutant in GDP-bound state enabled covalent inhibitor design, which Amgen and Mirati successfully translated into approved drugs.

Q3. Which mutation class represents the largest unmet clinical need in the RAS-acting agents market? ▼

KRAS G12D represents the largest unmet need, as it is the most prevalent KRAS mutation in pancreatic ductal adenocarcinoma — a cancer with virtually no effective targeted therapies and median survival under 12 months. No approved G12D-selective agent exists as of 2025, making this the most commercially consequential near-term pipeline readout in the entire oncology sector.

Q4. How does Medicare drug price negotiation under the Inflation Reduction Act affect RAS-acting agent pricing? ▼

Sotorasib entered the Medicare Drug Price Negotiation list in 2024, setting a precedent for price compression on newly approved small-molecule oncology agents with significant Medicare utilization. This structurally limits net revenue upside for US-approved RAS agents and increases pressure on pipeline companies to demonstrate superior efficacy justifying premium pricing against negotiated reference points.

Q5. What competitive dynamic most threatens Amgen's market leadership position by 2028? ▼

Revolution Medicines' pan-RAS platform directly threatens Amgen's position by offering mutation-agnostic RAS inhibition, which eliminates the mutation-selection advantage that currently differentiates Amgen's sotorasib from broader-spectrum competitors. If RMC-6236 achieves superior progression-free survival data versus sotorasib in G12C NSCLC in head-to-head or cross-trial comparisons, prescriber switching accelerates materially before patent expiry considerations become relevant.